Introduction
============

The incidence of fungal infections is a growing serious health burden worldwide, especially, in industrialized countries. Immunocompromised individuals are particularly more prone to life-threatening fungal infections caused by opportunistic fungi. In addition, the use of anticancer drugs and immunosupressant agents increases the incidence rate of serious fungal infections. The emergence of drug resistance and toxicity of the currently available antifungal agents (flucytosine, amphotericin B, and ketoconazole) have reinforced the demand for the development of new antifungal candidates with improved potency and safety profiles.[@b1-dddt-13-775],[@b2-dddt-13-775]

Azoles are successfully used for the treatment of serious fungal infections owing to their favorable pharmacokinetic parameters, high therapeutic index, and wide antifungal spectrum.[@b3-dddt-13-775] They inhibit the activity of lanosterol 14α-demethylase (CYP51) leading to prevention of ergosterol biosynthesis and hence the inability of fungi to grow normally.[@b4-dddt-13-775] Imidazole and triazole heterocylic rings constitute essential pharmacophore fragments of the clinically used antifungal azoles. Fluconazole and itraconazole are potent triazole-bearing antifungal drugs; however, the former drug is not effective against invasive aspergillosis and the latter one suffers from poor aqueous solubility and oral bioavailability.[@b5-dddt-13-775],[@b6-dddt-13-775] Therefore, there is an urgent medical need to develop new antifungal drug-like candidates bearing azole nuclei to overcome the drawbacks of the currently available azole antifungal agents.

Most of the available azole antifungal agents bear an ethyl spacer which separates the azole moiety from an aromatic pharmacophore fragment. However, a propyl spacer separating the azole pharmacophore from the aromatic part occurred in a limited number of antifungal candidates.[@b7-dddt-13-775]--[@b9-dddt-13-775] Accordingly, it was of our interest to report the synthesis of certain imidazole-based surrogates bearing a propyl spacer to be evaluated as new antifungal candidates. In addition, the title compounds **5a-r** bear 1,3-benzodioxole aromatic fragments which might augment their antifungal potential.[@b10-dddt-13-775],[@b11-dddt-13-775] The assigned chemical structures of the target compounds **5a-r** were thoroughly characterized using different spectroscopic techniques. Moreover, the configuration of the imine functionality of the title compounds **5a-r** were examined with the aid of single crystal X-ray analysis of compound **5o** as a representative example of the title compounds **5a-r**.

Materials and methods
=====================

General
-------

The uncorrected melting points of the synthesized compounds were measured using a Gallenkamp melting point device. A Perkin Elmer FT-IR Spectrum BX device was used to record the infrared (IR) spectra (as KBr disks). The nuclear magnetic resonance (NMR) spectra of the synthesized compounds were measured after dissolving the test samples in DMSO-*d*~6~ and he measurements were achieved at 500 MHz for ~1~H and 125.76 MHz for ~13~C on Bruker NMR spectrometer at the Research Center, College of Pharmacy, King Saud University, Saudi Arabia. Chemical shifts are articulated in δ-values (ppm) compared to tetramethylsilane as an internal standard. Elemental analyses of the target compounds were executed at the Microanalysis Laboratory, Cairo University, Cairo, Egypt, and the results agreed favorably with the proposed structure within ±0.4% of the theoretical values ([Table S1](#SD1-dddt-13-775){ref-type="supplementary-material"}). Agilent Quadrupole 6120 LC/MS was utilized to record the mass spectra of the synthesized compounds with the aid of electrospray ionization (ESI) source. Silica gel thin layer chromatography plates with fluorescent indicator at 254 nm were acquired from Merck and visualization was accomplished by illumination with a UV light source (254 nm).

Chemistry
---------

### Synthesis of 1-(2*H*-1,3-benzodioxol-5-yl)-3-(1*H-*imidazol-1-yl)propan-1-one (**3**)

Compound **3** was prepared according to the previously reported procedure and its spectral data are consistent with reported ones.[@b12-dddt-13-775]

### Synthesis of (1*E*)-1-(2*H*-1,3-benzodioxol-5-yl)-*N-*hydroxy-3-(1*H*-imidazol-1-yl) propan-1-imine (**4**)

Oxime **4** was synthesized from ketone **3** through adopting the reported method and its spectral data are consistent with the previously reported ones.[@b13-dddt-13-775]

General procedure for the synthesis of the target oximino esters **5a-r**
-------------------------------------------------------------------------

### Method A

*N*,*N*′-Carbonyldiimidazole (0.32 g, 2.0 mmol) was added to a stirred solution of the appropriate carboxylic acid (2.0 mmol) in tetrahydrofuran (THF) (10 mL). Oxime **4** (0.5 g, 2.0 mmol) was added to the stirred reaction mixture and stirring was continued for further 18 hours at room temperature. THF was evaporated under vacuum and ethyl acetate (30 mL) was added to the residue and the organic phase was washed successively with water (2×20 mL), 10% NaHCO~3~ solution (2×15 mL), and water (2×15 mL). The organic layer was separated, dried (Na~2~SO~4~), and evaporated under reduced pressure. The corresponding oximino esters **5a-d**, **5f**, **5g**, **5i**, **5l**, **5m**, and **5p-r** were purified either by recrystallization from ethanol (for solids) or column chromatography (for oils).

### Method B

4-Dimethylaminopyridine (400 mg) was added to a stirred solution of the appropriate carboxylic acid (7 mmol) and *N*-(3-dimethylaminopropyl)-*N*′-ethylcarbodiimide hydrochloride (EDCI⋅HCl, 1.39 g, 7.3 mmol) in dichloromethane (75 mL). Oxime **4** (1.79 g, 6.9 mmol) was added to the stirred reaction mixture and stirring was continued for further 18 hours at room temperature. The reaction mixture was washed successively with water (2×20 mL), 10% NaHCO~3~ solution (2×15 mL), and water (2×15 mL). The organic layer was separated, dried (Na~2~SO~4~), and evaporated under reduced pressure. The respective crude oximino esters **5e**, **5h**, **5j**, **5k**, **5n**, and **5o** were purified by recrystallization from ethanol.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1yl)propylidene\]amino}oxy)(phenyl)methanone (**5a**). Yield 0.28 g (28%); white powder, mp 130°C--132°C; IR (KBr): ν (cm^−1^) 3,099, 2,887, 1,739 (C=O), 1,600 (C=N), 1,504, 1,452, 1,232, 744; ~1~H-NMR (CDCl~3~): δ (ppm) 3.44 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 4.36 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.05 (s, 2H, --O--CH~2~--O--), 6.84 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.95 (s, 1H, --N--CH=CH--N=), 7.07 (s, 1H, --N--CH=CH--N=), 7.14 (d, *J* = 7.0 Hz, 1H, Ar-H), 7.32 (s, 1H, Ar-H), 7.52--7.55 (m, 2H, Ar-H), 7.64--7.66 (m, 1H, Ar-H), 7.83 (s, 1H, --N--CH=N--), 8.05 (d, *J* = 7.5 Hz, 2H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.7 (-CH~2~-CH~2~-N), 44.2 (--CH~2~--CH~2~--N), 101.8 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 119.1 (--N--CH=CH--N=), 122.1, 126.8, 128.7, 128.8, 129.5, 133.7 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 148.5, 150.5 (Ar-C), 162.6, 163.4 (C=N, C=O); MS m/z (ESI): 364.1 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1yl) propylidene\]amino}oxy)(4-bromophenyl)methanone (**5b**). Yield 0.34 g (34%); pale yellow powder, mp 92°C--94°C; IR (KBr): ν (cm^−1^) 3,107, 2,914, 1,726 (C=O), 1,589 (C=N), 1,504, 1,442, 1,265, 748; ~1~H-NMR (CDCl~3~): δ (ppm) 3.43 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 4.34 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.06 (s, 2H, --O--CH~2~--O--), 6.85 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.93 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.14 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.31 (d, *J* = 1.0 Hz, 1H, Ar-H), 7.67 (d, *J* = 8.5 Hz, 2H, Ar-H), 7.82 (s, 1H, --N--CH=N--), 7.87 (d, *J* = 8.5 Hz, 2H, Ar-H); ~13~C--NMR (CDCl~3~): δ (ppm) 30.6 (--CH~2~--CH~2~--N), 44.2 (--CH~2~--CH~2~--N), 101.9 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 119.1 (--N--CH=CH--N=), 122.1, 126.5, 127.5, 128.7, 128.9, 131.0, 132.2 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 148.6, 150.6 (Ar-C), 162.8, 162.9 (C=N, C=O); MS m/z (ESI): 442.0 \[M + H\]^+^, 444.0 \[(M + 2)+ H\]^+^, 445.0 \[(M + 3)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1yl) propylidene\]amino}oxy)(2-chlorophenyl)methanone (**5c**). Yield 0.53 g (53%); pale yellow viscous oil; IR (KBr): ν (cm^−1^) 3,016, 2,937, 1,739 (C=O), 1,604 (C=N), 1,510, 1,446, 1,253, 754; ~1~H-NMR (CDCl~3~): δ (ppm) 3.35 (t, *J* = 6.6 Hz, 2H, --CH~2~--CH~2~--N), 4.23 (t, *J* = 6.6 Hz, 2H, --CH~2~--CH~2~--N), 6.07 (s, 2H, --O--CH~2~--O--), 6.81 (d, *J* = 7.8 Hz, 1H, Ar-H), 6.86 (s, 1H, --N--CH=CH--N=), 6.98 (s, 1H, --N--CH=CH--N=), 7.09 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.26 (s, 1H, Ar-H), 7.40 (s, 1H, Ar-H), 7.42 (s, 1H, --N--CH=N--), 7.48--7.50 (m, 2H, Ar-H), 7.79 (d, *J* = 7.2 Hz, 1H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 31.0 (--CH~2~--CH~2~--N), 43.9 (--CH~2~--CH~2~--N), 101.8 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 118.7 (--N--CH=CH--N=), 122.1, 126.5, 127.0, 129.4, 129.8, 130.9, 131.7, 132.9, 133.1 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 148.5, 150.5 (Ar-C), 162.8, 163.3 (C=N, C=O); MS m/z (ESI): 398.1 \[M + H\]^+^, 399.1 \[(M + 1)+ H\]^+^, 400.1 \[(M + 2)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1yl) propylidene\]amino}oxy)(3-chlorophenyl)methanone (**5d**). Yield 0.39 g (39%); white powder, mp 118°C--121°C; IR (KBr): ν (cm^−1^) 3,064, 2,922, 1,735 (C=O), 16,24 (C=N), 1,575, 1,504, 1,232, 736; ~1~H-NMR (CDCl~3~): δ (ppm) = 3.40 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 4.30 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.06 (s, 2H, --O--CH~2~--O--), 6.85 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.94 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.13 (dd, *J* = 1.5, 8.0 Hz, 1H, Ar-H), 7.29--7.30 (m, 1H, Ar-H), 7.46--7.49 (m, 2H, --N--CH=N--, Ar-H), 7.63 (dd, *J* = 0.9, 7.9 Hz, 1H, Ar-H), 7.91 (d, *J* = 7.7 Hz, 1H, Ar-H), 8.01 (s, 1H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.7 (--CH~2~--CH~2~--N), 43.9 (--CH~2~--CH~2~--N), 101.9 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 118.8 (--N--CH=CH--N=), 122.1, 126.5, 127.7, 129.6, 130.0, 130.1, 130.4, 133.7, 134.9 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.9 (--N--CH=N--), 148.6, 150.6 (Ar-C), 162.3, 163.1 (C=N, C=O); MS m/z (ESI): 398.1 \[M + H\]^+^, 399.1 \[(M + 1)+ H\]^+^, 400.1 \[(M + 2)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1yl) propylidene\]amino}oxy)(4-chlorophenyl)methanone (**5e**). Yield 0.37 g (37%); white powder, mp 103°C--105°C; IR (KBr): ν (cm^−1^) 3,111, 2,912, 1,730 (C=O), 1,589 (C=N), 1,504, 1,444, 1,255, 750; ~1~H-NMR (CDCl~3~): δ (ppm) 3.43 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 4.34 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 6.05 (s, 2H, --O--CH~2~--O--), 6.84 (d, *J* = 8.5 Hz, 1H, Ar-H), 6.93 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.14 (dd, *J* = 1.5, 8.5 Hz, 1H, Ar-H), 7.29 (s, 1H, Ar-H), 7.48 (d, *J* = 8.5 Hz, 2H, Ar-H), 7.83 (s, 1H, --N--CH=N--), 7.94 (d, *J* = 8.5 Hz, 2H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.6 (--CH~2~--CH~2~--N), 44.2 (--CH~2~--CH~2~--N), 101.9 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 119.1 (--N--CH=CH--N=), 122.1, 126.5, 127.0, 128.6, 129.2, 130.9 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 140.2, 148.5, 150.6 (Ar-C), 162.6, 162.8 (C=N, C=O); MS m/z (ESI): 398.1 \[M + H\]^+^, 399.1 \[(M + 1)+ H\]^+^, 400.1 \[(M + 2)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(3-fluorophenyl)methanone (**5f**). Yield 0.4 g (40%); white powder, mp 135°C--137°C; IR (KBr): ν (cm^−1^) 3,007, 1,741 (C=O), 1,703 (C=N), 1,589, 1,506, 1,267, 746; ~1~H-NMR (DMSO-*d*~6~): δ (ppm) 3.47 (t, *J* = 6.0 Hz, 2H, --CH~2~--CH~2~--N), 4.27 (t, *J* = 6.1 Hz, 2H, --CH~2~--CH~2~--N), 6.14 (s, 2H, --O--CH~2~--O--), 6.78 (s, 1H, --N--CH=CH--N=), 7.04 (d, *J* = 8.6 Hz, 1H, Ar-H), 7.16 (s, 1H, --N--CH=CH--N=), 7.32 (s, 2H, Ar-H), 7.55 (s, 1H, --N--CH=N--), 7.60--7.67 (m, 2H, Ar-H), 7.77 (d, *J* = 8.8 Hz, 1H, Ar-H), 7.88 (d, *J* = 7.4 Hz, 1H, Ar-H); ~13~C-NMR (DMSO-*d*~6~): δ (ppm) 30.4 (--CH~2~--CH~2~--N), 43.7 (--CH~2~--CH~2~--N), 102.3 (--O--CH~2~--O--), 107.4, 108.9 (Ar-CH), 116.4, 119.8, 121.2, 121.3, 122.9, 126.1, 126.2, 127.1, 128.9 (Ar-CH, Ar--C, --N--CH=CH--N=, --N--CH=CH--N=), 137.6 (--N--CH=N--), 148.3, 150.3, 162.3, 163.5, 164.7 (Ar-C, C=N, C=O); MS m/z (ESI): 382.1 \[M + H\]^+^, 383.1 \[(M + 1)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl)propylidene\]amino}oxy)(4-fluorophenyl)methanone (**5g**). Yield 0.35 g (35%); white powder, mp 75°C--77°C; IR (KBr): ν (cm^−1^) 3,107, 2,920, 1,739 (C=O), 1,602 (C=N), 1,583, 1,506, 1,246, 756; ~1~H-NMR (CDCl~3~): δ (ppm) 3.40 (t, *J* = 6.9 Hz, 2H, --CH~2~--CH~2~--N), 4.30 (t, *J* = 6.9 Hz, 2H, --CH~2~--CH~2~--N), 6.05 (s, 2H, --O--CH~2~--O--), 6.85 (d, *J* = 8.1 Hz, 1H, Ar-H), 6.92 (s, 1H, --N--CH=CH--N=), 7.04 (s, 1H, --N--CH=CH--N=), 7.14 (dd, *J* = 1.5, 8.1 Hz, 1H, Ar-H), 7.18--7.22 (m, 2H, Ar-H), 7.28--7.29 (m, 1H, Ar-H), 7.57 (s, 1H, --N--CH=N--), 8.03--8.06 (m, 2H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.7 (--CH~2~--CH~2~--N), 43.9 (--CH~2~--CH~2~--N), 101.9 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 116.1 (d, *J* C-3′, F& C-5′, *F* = 22.1 Hz, C-3′ and C-5′), 118.9 (--N--CH=CH--N=), 122.1, 124.9, 126.7, 129.7 (Ar-CH, Ar--C, --N--CH=CH--N=), 132.2 (d, *J* C-2′, F& C-6′, *F* = 9.4 Hz, C-2′ and C-6′), 136.9 (--N--CH=N--), 148.5, 150.5, 162.6, 162.8, (Ar-C, C=N, C=O), 166.1 (d, *J* C-4′, *F* = 255.8 Hz, C-4′); MS m/z (ESI): 382.1 \[M + H\]^+^, 383.1 \[(M + 1)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(4-methoxyphenyl)methanone (**5h**). Yield 0.63 g (63%); white powder, mp 147°C--149°C; IR (KBr): ν (cm^−1^) 3,015, 2,966, 1,722 (C=O), 1,604 (C=N), 1,506, 1,440, 1,259, 740; ~1~H-NMR (CDCl~3~): δ (ppm) 3.41 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 3.90 (s, 3H, --OCH~3~), 4.34 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 6.03 (s, 2H, --O--CH~2~--O--), 6.82 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.95 (s, 1H, --N--CH=CH--N=), 6.98 (d, *J* = 8.5 Hz, 2H, Ar-H), 7.05 (s, 1H, --N--CH=CH--N=), 7.12 (dd, *J* = 1.5, 8.0 Hz, 1H, Ar-H), 7.30 (s, 1H, Ar-H), 7.79 (s, 1H, --N--CH=N--), 7.97 (d, *J* = 9.0 Hz, 2H, Ar-H.); ~13~C-NMR (CDCl~3~): δ (ppm) 30.7 (--CH~2~--CH~2~--N), 44.2 (--CH~2~--CH~2~--N), 55.6 (--OCH~3~), 101.8 (--O--CH~2~--O--), 107.1, 108.4, 114.1 (Ar-CH), 119.1 (--N--CH=CH--N=), 120.7, 122.0, 126.9, 128.7, 131.6 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 148.6, 150.4, 162.2 (Ar-C), 163.2, 163.9 (C=N, C=O); MS m/z (ESI): 394.1 \[M + H\]^+^, 416.1 \[M + 23\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(2-methylphenyl)methanone (**5i**). Yield 0.4 g (40%); pale yellow viscous oil; IR (KBr): ν (cm^−1^) 3,014, 2,966, 1,747 (C=O), 1,600 (C=N), 1,506, 1,444, 12,32, 710; ~1~H-NMR (CDCl~3~): δ (ppm) 2.64 (s, 3H, CH~3~), 3.35 (t, *J* = 6.6 Hz, 2H, --CH~2~--CH~2~--N), 4.24 (t, *J* = 6.6 Hz, 2H, --CH~2~--CH~2~--N), 6.02 (s, 2H, --O--CH~2~--O--), 6.82 (d, *J* = 8.4 Hz, 1H, Ar-H), 6.87 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.11 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.22--7.26 (m, 1H, Ar-H.), 7.30--7.32 (m, 2H, Ar-H.), 7.46 (t, *J* = 7.2 Hz, 1H, Ar-H.), 7.56 (s, 1H, --N--CH=N--), 7.77 (d, *J* = 7.8 Hz, 1H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 21.8 (CH~3~), 30.7 (--CH~2~--CH~2~--N), 44.0 (--CH~2~--CH~2~--N), 101.8 (--O--CH~2~--O--), 107.1, 108.4 (Ar-CH), 118.8 (--N--CH= CH--N=), 122.0, 125.9, 126.8, 128.0, 129.2, 129.7, 130.8, 132.0 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 140.8, 148.5, 150.4 (Ar-C), 162.1, 164.2 (C=N, C=O); MS m/z (ESI): 378.1 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(3-methylphenyl)methanone (**5j**). Yield 0.36 g (36%); white powder, mp 103°C--105°C; IR (KBr): ν (cm^−1^) 3,107, 2,978, 1,743 (C=O), 1,610 (C=N), 1,575, 1,502, 1,269, 720; ~1~H-NMR (CDCl~3~): δ (ppm) 2.45 (s, 3H, CH~3~), 3.42 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 4.34 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.03 (s, 2H, --O--CH~2~--O--), 6.83 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.96 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.14 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.30 (d, *J* = 1.5 Hz, 1H, Ar-H), 7.40--7.44 (m, 2H, Ar-H.), 7.74 (s, 1H, --N--CH=N--), 7.81 (d, *J* = 7.0 Hz, 1H, Ar-H), 7.85 (s, 1H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 21.4 (CH~3~), 30.7 (--CH~2~--CH~2~--N), 44.2 (--CH~2~--CH~2~--N), 101.8 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 119.1 (--N--CH=CH--N=), 122.1, 126.6, 126.8, 128.6, 128.7, 128.8, 130.1, 134.5 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 138.7, 148.5, 150.5 (Ar-C), 162.6, 163.6 (C=N, C=O); MS m/z (ESI): 378.1 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(4-methylphenyl)methanone (**5k**). Yield 0.3 g (30%); pale yellow powder, mp 73°C--76°C; IR (KBr): ν (cm^−1^) 3,107, 2,920, 1,722 (C=O), 1,612 (C=N), 1,581, 1,504, 1,265, 742; ~1~H-NMR (CDCl~3~): δ (ppm) 2.41 (s, 3H, CH~3~), 3.41 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 4.33 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.04 (s, 2H, --O--CH~2~--O--), 6.84 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.95 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.13 (d, *J* = 7.5 Hz, 1H, Ar-H), 7.30 (s, 1H, Ar-H), 7.32 (d, *J* = 8.0 Hz, 2H, Ar-H.), 7.67 (s, 1H, --N--CH=N--), 7.93 (d, *J* = 8.0 Hz, 2H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 21.8 (CH~3~), 30.8 (--CH~2~--CH~2~--N), 44.1 (--CH~2~--CH~2~--N), 101.7 (--O--CH~2~--O--), 107.2, 108.5 (Ar-CH), 118.9 (--N--CH=CH--N=), 122.0, 125.8 (Ar-CH), 126.9, 129.2, 129.5, 129.6 (Ar--C, --N--CH=CH--N=), 136.9 (--N--CH=N--), 144.6, 148.5, 150.4 (Ar-C), 162.4, 163.5 (C=N, C=O); MS m/z (ESI): 378.1 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl)propylidene\]amino}oxy)\[(3-(trifluoromethyl)phenyl)\] methanone (**5l**). Yield 0.38 g (38%); white powder, mp 129°C--131°C; IR (KBr): ν (cm^−1^) 3,089, 1,753 (C=O), 1,612 (C=N), 1,579, 1,500, 1,228, 744; ~1~H-NMR (DMSO-*d*~6~): δ (ppm) 3.48 (t, *J* = 6.4 Hz, 2H, --CH~2~--CH~2~--N), 4.29 (t, *J* = 6.4 Hz, 2H, --CH~2~--CH~2~--N), 6.14 (s, 2H, --O--CH~2~--O--), 6.77 (s, 1H, --N--CH=CH--N=), 7.04 (d, *J* = 8.6 Hz, 1H, Ar-H), 7.16 (s, 1H, --N--CH=CH--N=), 7.34--7.36 (m, 2H, Ar-H), 7.54 (s, 1H, --N--CH=N--), 7.84--7.87 (m, 1H, Ar-H), 8.11 (d, *J* = 7.5 Hz, 1H, Ar-H), 8.24 (s, 1H, Ar-H), 8.31 (d, *J* = 7.6 Hz, 1H, Ar-H); ~13~C-NMR (DMSO-*d*~6~): δ (ppm) 30.5 (--CH~2~--CH~2~--N), 43.8 (--CH~2~--CH~2~--N), 102.3 (--O--CH~2~--O--), 107.4, 108.9 (Ar-CH), 119.8 (--N--CH=CH--N=), 122.9, 126.1, 126.2, 127.0, 128.9, 130.0, 130.7, 130.8, 130.9, 133.8 (Ar-CH, Ar--C, --N--CH=CH--N=), 137.6, 148.4, 150.4 (--N--CH=N--, Ar-C), 162.2, 164.8 (C=N, C=O); MS m/z (ESI): 432.1 \[M + H\]^+^, 433.1 \[(M + 1)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl)propylidene\]amino}oxy)\[(4-(trifluoromethyl)phenyl)\] methanone (**5m**). Yield 0.35 g (35%); white powder, mp 136°C--138°C; IR (KBr): ν (cm^−1^) 3,026, 2,939, 1,741 (C=O), 1,624 (C=N), 1,577, 1,510, 1,251, 742; ~1~H-NMR (DMSO-*d*~6~): δ (ppm) 3.48 (t, *J* = 6.3 Hz, 2H, --CH~2~--CH~2~--N), 4.28 (t, *J* = 6.4 Hz, 2H, --CH~2~--CH~2~--N), 6.14 (s, 2H, --O--CH~2~--O--), 6.79 (s, 1H, --N--CH=CH--N=), 7.04 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.16 (s, 1H, --N--CH=CH--N=), 7.32--7.34 (m, 2H, Ar-H), 7.56 (s, 1H, --N--CH=N--), 7.96 (d, *J* = 8.0 Hz, 2H, Ar-H.), 8.22 (d, *J* = 7.9 Hz, 2H, Ar-H); ~13~C-NMR (DMSO-*d*~6~): δ (ppm) 30.4 (--CH~2~--CH~2~--N), 43.6 (--CH~2~--CH~2~--N), 102.3 (--O--CH~2~--O--), 107.4, 108.9 (Ar-CH), 119.9 (--N--CH=CH--N=), 122.9, 126.3, 126.4, 127.0, 128.9, 130.8, 132.7, 133.5 (Ar-CH, Ar--C, --N--CH=CH--N=), 137.7 (--N--CH=N--), 148.4, 150.3 (Ar-C), 162.3, 164.8 (C=N, C=O); MS m/z (ESI): 432.1 \[M + H\]^+^, 433.1 \[(M + 1)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(3,4-dichlorophenyl)methanone (**5n**). Yield 0.48 g (48%); white powder, mp 180°C--183°C; IR (KBr): ν (cm^−1^) 3,088, 2,958, 1,737 (C=O), 1,573 (C=N), 1,506, 1,469, 1,230, 748; ~1~H-NMR (CDCl~3~): δ (ppm) 3.38 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 4.29 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.07 (s, 2H, --O--CH~2~--O--), 6.86 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.93 (s, 1H, --N--CH=CH--N=), 7.05 (s, 1H, --N--CH=CH--N=), 7.15 (dd, *J* = 1.0, 8.0 Hz, 1H, Ar-H), 7.30 (s, 1H, Ar-H), 7.53 (s, 1H, --N--CH=N--), 7.60 (d, *J* = 8.0 Hz, 1H, Ar-H.), 7.82 (dd, *J* = 1.5, 8.0 Hz, 1H, Ar-H), 8.08 (d, *J* = 1.5 Hz, 1H, Ar-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.7 (--CH~2~--CH~2~--N), 43.9 (--CH~2~--CH~2~--N), 101.9 (--O--CH~2~--O--), 107.2, 108.6 (Ar-CH), 118.8 (--N--CH=CH--N=), 122.2, 126.3, 128.5, 128.6, 130.0, 131.0, 131.4, 133.4 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.9 (--N--CH=N--), 138.4, 148.6, 150.7 (Ar-C), 161.7, 163.2 (C=N, C=O); MS m/z (ESI): 432.0 \[M + H\]^+^, 433.0 \[(M + 1)+ H\]^+^, 434.0 \[(M + 2)+ H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl)propylidene\]amino}oxy)(3,4,5-trimethoxyphenyl) methanone (**5o**). Yield 0.65 g (65%); white powder, mp 178°C--180°C; IR (KBr): ν (cm^−1^) 3,109, 2,941, 1,739 (C=O), 1,583 (C=N), 1,502, 1,462, 1,240, 736; ~1~H-NMR (CDCl~3~): δ (ppm) 3.40 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 3.94 (s, 6H, 2 x --OCH~3~), 3.95 (s, 3H, --OCH~3~), 4.30 (t, *J* = 7.0 Hz, 2H, --CH~2~--CH~2~--N), 6.05 (s, 2H, --O--CH~2~--O--), 6.85 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.93 (s, 1H, --N--CH=CH--N=), 7.04 (s, 1H, --N--CH=CH--N=), 7.12 (dd, *J* = 1.5, 8.0 Hz, 1H, Ar-H), 7.28--7.29 (m, 3H, Ar-H), 7.51 (s, 1H, --N--CH=N--); ~13~C-NMR (CDCl~3~): δ (ppm) 30.8 (--CH~2~--CH~2~--N), 43.9 (--CH~2~--CH~2~--N), 56.4, 61.0 (--OCH~3~), 101.9 (--O--CH~2~--O--), 106.9, 107.2, 108.5 (Ar-CH), 118.7 (--N--CH=CH--N=), 122.1, 123.5, 126.7, 130.0 (Ar-CH, Ar--C, --N--CH=CH--N=), 136.8 (--N--CH=N--), 143.0, 148.5, 150.5, 153.2 (Ar-C), 162.8, 163.2 (C=N, C=O); MS m/z (ESI): 454.2 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(pyridine-4-yl)methanone (**5p**). Yield 0.44 g (44%); white powder, mp 175°C--177°C; IR (KBr): ν (cm^−1^) 3,145, 2,914, 1,747 (C=O), 1,589 (C=N), 1,504, 1,442, 1,230, 729; ~1~H-NMR (CDCl~3~): δ (ppm) 3.48 (t, *J* = 6.5 Hz, 2H, --CH2--CH2--N), 4.28 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 6.14 (s, 2H, --O--CH~2~--O--), 6.77 (s, 1H, --N--CH=CH--N=), 7.03 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.16 (s, 1H, --N--CH=CH--N=), 7.32 (s, 1H, Ar-H), 7.33 (s, 1H, Ar-H), 7.55 (s, 1H, --N--CH=N--), 7.91 (dd, *J* = 1.5, 4.5 Hz, 2H, pyridine-H), 8.86 (dd, *J* = 1.5, 4.5 Hz, 2H, pyridine-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.4 (--CH~2~--CH~2~--N), 43.6 (--CH~2~--CH~2~--N), 102.3 (--O--CH~2~--O--), 107.4, 108.9 (Ar-CH), 119.9 (--N--CH=CH--N=), 123.0, 123.1, 126.9 (Ar-CH), 128.9 (--N--CH=CH--N=), 136.2 (--N--CH=N--), 137.7, 148.3, 150.4,151.3 (Ar-C), 162.2, 165.1 (C=N, C=O); MS m/z (ESI): 365.1 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl)propylidene\]amino}oxy)(thiophen-2-yl)methanone (**5q**). Yield 0.28 g (28%); white powder, mp 149°C--151°C; IR (KBr): ν (cm^−1^) 3,099, 2,889, 1,734 (C=O), 1,577 (C=N), 1,504, 1,452, 1,246, 729; ~1~H-NMR (CDCl~3~): δ (ppm) 3.42 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 4.27 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 6.13 (s, 2H, --O--CH~2~--O--), 6.82 (s, 1H, --N--CH=CH--N=), 7.02 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.18 (s, 1H, --N--CH=CH--N=), 7.29--7.33 (m, 3H, Ar-H, thiophene-H), 7.58 (s, 1H, --N--CH=N--), 7.97 (dd, *J* = 1.0, 3.5 Hz, 1H, thiophene-H), 8.08 (dd, *J* = 1.0, 4.5 Hz, 1H, thiophene-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.5 (--CH~2~--CH~2~--N), 43.5 (--CH~2~--CH~2~--N), 102.3 (--O--CH~2~--O--), 107.4, 108.9 (Ar-CH), 119.8 (--N--CH=CH--N=), 122.9, 127.1, 128.9, 129.1 (Ar-CH), 131.3 (--N--CH=CH--N=), 135.1, 135.3, (Ar-C) 137.6, (--N--CH=N--) 148.3, 150.2 (Ar-C), 159.0, 163.9 (C=N, C=O); MS m/z (ESI): 370.1 \[M + H\]^+^.

({\[(1*E*)--1-(1,3-Benzodioxol-5-yl)--3-(1*H*-imidazol-1-yl) propylidene\]amino}oxy)(thiophen-3-yl)methanone (**5r**). Yield 0.43 g (43%); white powder, mp 138°C--140°C; IR (KBr): ν (cm^−1^) 3,144, 2,887, 1,739 (C=O), 1,577 (C=N), 1,504, 1,450, 1,230, 727; ~1~H-NMR (CDCl~3~): δ (ppm) 3.44 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 4.26 (t, *J* = 6.5 Hz, 2H, --CH~2~--CH~2~--N), 6.13 (s, 2H, --O--CH~2~--O--), 6.79 (s, 1H, --N--CH=CH--N=), 7.01 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.16 (s, 1H, --N--CH=CH--N=), 7.28--7.29 (m, 2H, Ar-H), 7.56 (s, 1H, --N--CH=N--), 7.57 (d, *J* = 5.5 Hz, 1H, thiophene-H), 7.75 (dd, *J* = 3.0, 5.0 Hz, 1H, thiophene-H), 8.53 (d, *J* = 1.5 Hz, 1H, thiophene-H); ~13~C-NMR (CDCl~3~): δ (ppm) 30.3 (--CH~2~--CH~2~--N), 43.6 (--CH~2~--CH~2~--N), 102.2 (--O--CH~2~--O--), 107.4, 108.9 (Ar-CH), 119.9 (--N--CH=CH--N=), 122.8, 127.3, 127.9, 128.4 (Ar-CH), 128.9 (--N--CH=CH--N=), 131.4, 135.1, (Ar-C) 137.7, (--N--CH=N--), 148.3, 150.1 (Ar-C), 159.5, 163.9 (C=N, C=O); MS m/z (ESI): 370.1 \[M + H\]^+^.

Crystal structure determination of compound **5o**
--------------------------------------------------

Compound **5o** was obtained as single crystals by slow evaporation from ethanol solution of the pure compound at room temperature. Data were collected on a Bruker APEX-II D8 Venture area diffractometer, equipped with graphite monochromatic Mo *K*α radiation, λ=0.71073 Å at 293 (2) K. Cell refinement and data reduction were carried out by Bruker SAINT. SHELXT[@b14-dddt-13-775] was used to solve the structure. The final refinement was carried out by full-matrix least-squares techniques with anisotropic thermal data for non-hydrogen atoms on F. CCDC 1875757 contains the supplementary crystallographic data for this compound and can be obtained free of charge from the Cambridge Crystallographic Data Centre via [www.ccdc.cam.ac.uk/data_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif).

Antifungal activity of the title compounds **5a-r**
---------------------------------------------------

The in vitro antifungal potential of the oximino esters **5a-r** was examined with the aid of diameter of the inhibition zone (DIZ) and minimum inhibitory concentration (MIC) assays according to literature methods.[@b12-dddt-13-775] The detailed experimental procedures are provided under the "Antifungal activity" section of in the Supplementary materials.

Results and discussion
======================

Chemistry
---------

The adopted synthetic pathway to prepare the title compounds **5a-r** is portrayed in [Scheme 1](#f3-dddt-13-775){ref-type="fig"}. Thus, the reaction sequence was commenced via conducting a Mannich reaction on the commercially available 1,3-benzodioxole derivative **1** to achieve oxime **3** in a three-step reaction sequence according to the reported methods.[@b13-dddt-13-775] Compound **3** was subjected to esterification with the appropriate carboxylic acid under mild conditions to furnish the target oximino esters **5a-r** in acceptable yields.

Crystal structure of compound **5o**
------------------------------------

The crystallographic data and refinement information of compound **5o**, C~23~H~24~N~4~O~6~, are summarized in [Table 1](#t1-dddt-13-775){ref-type="table"}. The selected bond lengths and bond angles for compound **5o** are presented in [Table 2](#t2-dddt-13-775){ref-type="table"}. The asymmetric unit contains one independent molecule as shown in [Figure 1](#f1-dddt-13-775){ref-type="fig"}. The 1,3-benzodioxole plane makes dihedral angles 5.69° and 77.56° with trimethoxyphenyl ring and imidazole ring, respectively. All the bond lengths and angles are in normal ranges.[@b15-dddt-13-775] The molecules are packed together in the crystal structure by three non-classical hydrogen bonds along the *b* axis as shown in [Table 3](#t3-dddt-13-775){ref-type="table"} and [Figure 2](#f2-dddt-13-775){ref-type="fig"}.

Antifungal activity of the target oximino esters **5a-r**
---------------------------------------------------------

The antifungal activity of the synthesized oximino esters **5a-r** is presented in [Table 4](#t4-dddt-13-775){ref-type="table"}. Compounds **5a**, **5g**, **5j**, **5l**, and **5m** showed the best antifungal activity against the tested *Candida albicans* strain in the DIZ assay with DIZ value of 15 mm being about 1.2-fold less potent than fluconazole. Whereas, compounds **5a**, **5b**, **5d-f**, and **5k-r** were the most active oximino esters against the tested *Candida tropicalis* strain in the DIZ assay with DIZ values equal to or more than 20 mm being nearly equipotent with fluconazole. Regarding the tested *Candida parapsilosis* and *Aspergillus niger* strains, compounds **5a-r** displayed moderate activity in the DIZ assay with DIZ values ranging from 11 to 23 mm, being nearly equipotent with fluconazole. Moreover, compounds **5l** and **5m** (bearing trifluoromethylphenyl moiety) were the most active equipotent congeners in the MIC assay against the tested *C. albicans* strain with MIC value of 0.148 μmol/mL, being about threefold less potent than fluconazole whereas, compound **5b**, bearing the 4-bromophenyl fragment, was the most active oximino ester toward *C. tropicalis* with MIC value of 0.289 μmol/mL, being about six times less potent than fluconazole, followed by the equipotent candidates **5l** and **5m** which displayed MIC value of 0.297 μmol/mL. Compound **5o** incorporating 3,4,5-trimethoxyphenyl moiety exhibited the best activity against the tested *C. parapsilosis* with MIC value of 0.141 μmol/mL, being nearly threefold less potent than fluconazole. The oximino ester **5l** was the most active anti-*A. niger* compound with MIC value of 0.297 μmol/mL, being equipotent with compound **5m**. Furthermore, compounds **5h**, **5i**, **5n**, and **5q** manifested the weakest antifungal activity among the synthesized oximino esters **5a-r** toward *C. tropicalis*, *C. parapsilosis*, *C. albicans*, and *A. niger*, respectively, with MIC values equal to or more than 1.18 μmol/mL. In summary, it seems that substitution with the 3- or 4-trifluoromethyl moiety (compounds **5l** and **5m**) is favored for the antifungal potential of the prepared oximino esters **5a-r**, particularly toward *C. albicans* and *A. niger*. On the other hand, the best anti-*C. tropicalis* and anti- *C. parapsilosis* activity was achieved with 4-bromophenyl (compound **5b**) and 3,4,5-trimethoxyphenyl (compound **5o**) moieties, respectively. Regarding the heteroaryl-bearing oximino esters (compounds **5p-r**), the thiophene-bearing compound **5r** is the best heteroaryl-bearing oximino ester against both *C. tropicalis* (MIC value =0.347 μmol/mL) and *A. niger* (MIC value =0.693 μmol/mL), and the pyridine-bearing compound, **5p**, is the best heteroaryl-bearing oximino ester against *C. parapsilosis* (MIC value =0.176 μmol/mL). The weak to moderate antifungal activity of the synthesized compounds **5a-r** as compared to the reference antifungal drugs might be attributed to either their poor pharmacokinetic properties or improper interaction with their target fungal protein.

Conclusion
==========

The synthesis and spectroscopic identification of certain new oximino esters **5a-r** bearing imidazole and 1,3-benzodioxole fragments have been reported. Single-crystal X-ray analysis of compound **5o** confirmed without doubt the assigned chemical structures of the title compounds as well as confirmed the (*E*)-configuration of their oximino group. The antifungal potentials of the title compounds **5a-r** have been examined in vitro against four fungal strains using DIZ and MIC assays. It seems that substitution with the 3- or 4-trifluoromethyl moiety (compounds **5l** and **5m**) is favored for the antifungal potential of the prepared oximino esters **5a-r**, particularly toward *C. albicans* and *A. niger*. On the other hand, the best anti- *C. tropicalis* and anti-*C. parapsilosis* activity was achieved with 4-bromophenyl (compound **5b**) and 3,4,5-trimethoxyphenyl (compound **5o**) moieties, respectively. The results of the current investigation could support the development of new antifungal lead candidates.

Supporting materials
====================

The details of the experimental methods which were adopted for the antifungal evaluation of the prepared compounds and representative NMR spectra ([Figures S1](#SD1-dddt-13-775){ref-type="supplementary-material"}[](#SD2-dddt-13-775){ref-type="supplementary-material"}[](#SD3-dddt-13-775){ref-type="supplementary-material"}[](#SD4-dddt-13-775){ref-type="supplementary-material"}[](#SD5-dddt-13-775){ref-type="supplementary-material"}--[S6](#SD6-dddt-13-775){ref-type="supplementary-material"}) of the target compounds are provided as Supplementary materials.

Supplementary materials
=======================

Antifungal activity
-------------------

### Materials

The reference standard antifungal drug, ketoconazole, was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Liquid RPMI 1640 medium supplemented with L-glutamine was obtained from Gibco-BRL, Life Technologies (Paisley, Scotland). Sabouraud Dextrose Agar (SDA) was obtained from Merck Co. (Darmstadt, Germany). Dimethyl sulfoxide (100%) was used to dissolve ketoconazole, and/or the tested compound 4 to give an initial concentration of 2,048 mg/L.

### Organisms

The used fungal strains are *Candida albicans* (ATCC 90028), *Candida tropicalis* (ATCC 66029), *Candida parapsilosis* (ATCC 22019) and *Aspergillus niger* (ATCC 16404).

### Preparation of fungal inocula

The inocula of the standard mold *Aspergillus niger* strain have been prepared by removing the sporulated *A. niger* from the Sabouraud Dextrose agar slant with a microbiological loop and the spores have been suspended in 10 mL of sterile water. The suspension has been filtered through sterile gauze to remove hyphae. The resulting suspension of conidia has been vigorously mixed using a vortex. The suspension has been adjusted to 1×10^5^ CFU/mL using spectrophotometer. This fungal suspension has been diluted 1:5 with RPMI medium to obtain suspensions having 2× of the required final concentration. This conidial suspension had a final concentration of 1×10^4^ CFU/mL when mixed with the tested solution of compound 4. On the other hand, the inocula of the standard yeast strains of *C. albicans*, *C. tropicalis* and *C. parapsilosis* have been prepared by suspending five representative colonies, obtained from 24 to 48 h culture on Sabauraud Dextrose agar medium, in sterile distilled water. The final inoculum concentration must be between 0.5×10^5^ and 2.5×10^5^ CFU/mL.

### Preparation of the tested compound solution

Briefly, a twofold dilution series of the tested compounds has been prepared in a double strength RPMI 1640 culture medium. Ten serial dilutions were prepared to give concentrations ranged from 1,024 mg/L to 2 mg/L.

### Antifungal susceptibility studies

Minimum Inhibitory Concentrations (MICs) have been determined by broth microdilution testing as described previously by EUCAST.[@b16-dddt-13-775] The experiment was carried out in duplicate. Briefly, one mL of RPMI 1640 medium from each of the bottle containing the corresponding concentration of the tested compounds has been transferred into sterile 7 mL Sterilin tubes (Thermo Fisher Scientific, Waltham, MA, USA). The RPMI 1640 medium containing 1,024 mg/L of the tested compounds has been dispensed to tube 1, the medium containing 512 mg/L has been dispensed to tube 2, the medium containing 256 mg/L has been dispensed to tube 3 and so on to tube 10 for the medium containing 2 mg/L of the tested compounds. One mL of the medium has been dispensed in tubes 11 (positive control) and 12 (negative control). One mL of the diluted inoculum suspension has transferred to each tube except tube 12 to bring the tested compounds dilutions to the required final test concentrations. The tubes were incubated at 35°C for 72 h. The MICs of the tested compounds were determined visually by recording the degree of growth inhibition in each tube. The microanalysis results ([Table S1](#SD7-dddt-13-775){ref-type="supplementary-material"}) of the target compounds **5a-r** agreed favorably with the proposed structures within ±0.4% of the theoretical values.

###### 

^1^H NMR spectrum of compound **5d**.

###### 

^13^C NMR spectrum of compound **5d**.

###### 

^1^H NMR spectrum of compound **5e**.

###### 

^13^C NMR spectrum of compound **5e**.

###### 

^1^H NMR spectrum of compound **5k**.

###### 

^13^C NMR spectrum of compound **5k**.

###### 

Microanalysis data of the title compounds **5a--r**

  Compound no    Elemental analysis                  
  -------------- -------------------- -------------- ---------------
                                                     
  **5a**         Calcd.: 66.11        Calcd.: 4.72   Calcd.: 11.56
  Found: 66.34   Found: 4.53          Found: 11.26   
                                                     
  **5b**         Calcd.: 54.31        Calcd.: 3.65   Calcd.: 9.50
  Found: 54.65   Found: 3.84          Found: 9.42    
                                                     
  **5c**         Calcd.: 60.38        Calcd.: 4.05   Calcd.: 10.56
  Found: 59.99   Found: 4.15          Found: 10.36   
                                                     
  **5d**         Calcd.: 60.38        Calcd.: 4.05   Calcd.: 10.56
  Found: 60.72   Found: 4.41          Found: 10.22   
                                                     
  **5e**         Calcd.: 60.38        Calcd.: 4.05   Calcd.: 10.56
  Found: 60.11   Found: 3.75          Found: 10.84   
                                                     
  **5f**         Calcd.: 62.99        Calcd.: 4.23   Calcd.: 11.02
  Found: 62.76   Found: 3.98          Found: 11.28   
                                                     
  **5g**         Calcd.: 62.99        Calcd.: 4.23   Calcd.: 11.02
  Found: 62.83   Found: 4.16          Found: 11.09   
                                                     
  **5h**         Calcd.: 64.12        Calcd.: 4.87   Calcd.: 10.68
  Found: 66.86   Found: 4.69          Found: 10.97   
                                                     
  **5i**         Calcd.: 66.83        Calcd.: 5.07   Calcd.: 11.13
  Found: 66.69   Found: 4.99          Found: 10.89   
                                                     
  **5j**         Calcd.: 66.83        Calcd.: 5.07   Calcd.: 11.13
  Found: 67.01   Found: 5.33          Found: 11.46   
                                                     
  **5k**         Calcd.: 66.83        Calcd.: 5.07   Calcd.: 11.13
  Found: 66.54   Found: 4.78          Found: 11.49   
                                                     
  **5l**         Calcd.: 58.47        Calcd.: 3.74   Calcd.: 9.74
  Found: 58.26   Found: 3.64          Found: 9.44    
                                                     
  **5m**         Calcd.: 58.47        Calcd.: 3.74   Calcd.: 9.74
  Found: 58.74   Found: 3.36          Found: 9.98    
                                                     
  **5n**         Calcd.: 55.57        Calcd.: 3.50   Calcd.: 9.72
  Found: 55.89   Found: 3.63          Found: 9.43    
                                                     
  **5o**         Calcd.: 60.92        Calcd.: 5.11   Calcd.: 9.27
  Found: 60.69   Found: 4.96          Found: 9.56    
                                                     
  **5p**         Calcd.: 62.63        Calcd.: 4.43   Calcd.: 15.38
  Found: 62.96   Found: 4.08          Found: 15.76   
                                                     
  **5q**         Calcd.: 58.53        Calcd.: 4.09   Calcd.: 11.38
  Found: 56.32   Found: 4.47          Found: 11.19   
                                                     
  **5r**         Calcd.: 58.53        Calcd.: 4.09   Calcd.: 11.38
  Found: 58.69   Found: 3.99          Found: 11.68   
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![ORTEP diagram of compound **5o**.\
**Note:** Displacement ellipsoids are plotted at the 40% probability level for non-H atoms. **Abbreviation:** ORTEP, Oak Ridge Thermal-Ellipsoid Plot Program.](dddt-13-775Fig1){#f1-dddt-13-775}

![Molecular packing of compound **5o** enables the viewing of hydrogen bonds which are drawn as dashed lines along *b* axis.](dddt-13-775Fig2){#f2-dddt-13-775}

![Synthesis of the target compounds **5a-r**. Reagents and conditions: (i) HN(CH~3~)~2~.HCl, (CH~2~O)~n~, concentrated HCl, ethanol, reflux, 2 hours; (ii) imidazole, water, reflux, 5 hours; (iii) H~2~NOH.HCl, KOH, ethanol, reflux, 18 hours; (iv) *N,N*′-carbonyldiimidazole, ArCOOH, THF, rt, 18 hours, for compounds **5a-d**, **5f**, **5g**, **5i**, **5l**, **5m**, and **5p-r**; and (v) ArCOOH, EDCI.HCl, DMAP, DCM, rt, 18 hours, for compounds **5e**, **5h**, **5j**, **5k**, **5n**, and **5o**.\
**Abbreviations:** DCM, dichloromethane; DMAP, 4-dimethylaminopyridine; rt, room temperature; THF, tetrahydrofuran.](dddt-13-775Fig3){#f3-dddt-13-775}

###### 

The crystallographic data and refinement information of compound **5o**

  -------------------------------------------------------------------- ------------------------------------------------------------------------
  **Crystal data**                                                     
  Molecular formula                                                    C~23~H~24~N~4~O~6~
  Molecular weight                                                     452.46
  Crystal system, space group                                          Triclinic, *P*-1
  Temperature (K)                                                      293
  *a*, *b*, *c* (Å)                                                    9.898 (3), 10.433 (3), 11.677 (4)
  *α*,*β*,*γ* (°)                                                      86.886 (6), 87.071 (7), 64.385 (6)
  V (Å[@b3-dddt-13-775])                                               1,085.2 (6)
  *Z*                                                                  2
  Radiation type                                                       Mo *K*α
  μ (mm^−1^)                                                           0.10
  Crystal size (mm)                                                    0.15×0.08×0.08
  **Data collection**                                                  
  Diffractometer                                                       Bruker APEX-II D8 venture diffractometer
  Absorption correction                                                Multi-scan SADABS Bruker 2014
  T~min~, T~max~                                                       0.862, 0.903
  No of measured, independent, and observed \[I\>2σ(I)\] reflections   24,341, 3,808, 1,363
  R~int~                                                               0.408
  **Refinement**                                                       
  R\[*F*^2^ \>2σ(*F*^2^)\], wR(*F*^2^), S                              0.100, 0.263, 1.02
  No of reflections                                                    3,808
  No of parameters                                                     301
  No of restraints                                                     0
  H-atom treatment                                                     H atoms treated by a mixture of independent and constrained refinement
  Δρ~max~, Δρ~min~ (e Å^−3^)                                           0.42, −0.56
  -------------------------------------------------------------------- ------------------------------------------------------------------------

###### 

Selected geometric parameters (Å, °) of compound **5o**

  -------------- ------------ -------------- ------------
  O1--C1         1.374 (10)   O6--C23        1.428 (8)
  O1--C7         1.434 (9)    N1--C10        1.461 (9)
  O2--C6         1.374 (9)    N1--C11        1.358 (11)
  O2--C7         1.417 (9)    N1--C13        1.329 (10)
  O3--C14        1.220 (9)    N2--C12        1.344 (12)
  O4--C17        1.354 (8)    N2--C13        1.314 (13)
  O4--C21        1.427 (10)   N3--N4         1.423 (8)
  O5--C18        1.360 (10)   N3--C8         1.296 (9)
  O5--C22        1.358 (11)   N4--C14        1.341 (8)
  O6--C19        1.359 (9)                   
  C1--O1--C7     106.0 (5)    N3--C8--C4     112.5 (6)
  C6--O2--C7     105.5 (5)    N3--C8--C9     124.1 (6)
  C17--O4--C21   118.6 (6)    N1--C10--C9    112.5 (6)
  C18--O5--C22   123.8 (6)    N1--C11--C12   106.1 (7)
  C19--O6--C23   118.0 (5)    N2--C12--C11   111.3 (8)
  C10--N1--C11   129.0 (6)    N1--C13--N2    113.9 (8)
  C10--N1--C13   125.7 (7)    O3--C14--C15   124.4 (6)
  C11--N1--C13   105.3 (7)    O3--C14--N4    122.8 (7)
  C12--N2--C13   103.3 (7)    N4--C14--C15   112.6 (6)
  N4--N3--C8     109.3 (6)    O4--C17--C16   123.8 (7)
  N3--N4--C14    114.9 (5)    O4--C17--C18   117.1 (7)
  O1--C1--C2     129.2 (7)    O5--C18--C17   123.5 (6)
  O1--C1--C6     109.0 (6)    O5--C18--C19   116.9 (7)
  O2--C6--C5     128.4 (6)    O6--C19--C18   114.3 (6)
  O2--C6--C1     110.8 (6)    O6--C19--C20   125.2 (6)
  O1--C7--O2     108.4 (6)                   
  -------------- ------------ -------------- ------------

###### 

Hydrogen-bond geometry (Å, °) of compound **5o**

  D--H ··· A            D--H     H ··· A   D ··· A            D--H ··· A
  --------------------- -------- --------- ------------------ ------------
                                                              
  C3--H3A···N2^i^       0.9300   2.5400    3.420              157.00
  C10--H10B···O3^ii^    0.9700   2.6000    \(10\) 3.435 (9)   145.00
  C21--H21A···O1^iii^   0.9600   2.4600    3.406 (9)          169.00

**Notes:** Symmetry codes: (i) −x+2, −y, −z+1; (ii) −x+1, −y+1, −z+1; (iii) x, y+1, z+1.

###### 

Antifungal potential of the target oximino esters **5a-r** against *C. albicans*, *C. tropicalis*, *C. parapsilosis*, and *A. niger*

  Compound no    *Candida albicans*   *Candida tropicalis*   *Candida parapsilosis*   *Asperagillus niger*                                
  -------------- -------------------- ---------------------- ------------------------ ---------------------- --------- -------- --------- -------
                                                                                                                                          
  **5a**         15±0.60              0.705                  22±0.40                  0.352                  19±0.58   0.352    14±0.58   0.705
  **5b**         14±0.40              0.579                  20±0.30                  0.289                  18±0.20   0.145    15±1.20   0.579
  **5c**         9±0.20               0.322                  17±0.50                  0.644                  13±0.50   \>1.29   13±0.40   0.644
  **5d**         13±0.40              0.644                  21±1.00                  0.322                  19±1.00   0.161    13±0.50   0.644
  **5e**         13±0.58              0.322                  21±0.50                  0.644                  18±0.58   0.322    11±0.40   1.29
  **5f**         14±0.30              0.671                  22±0.60                  0.336                  17±1.00   0.336    13±0.60   0.671
  **5g**         15±0.50              0.168                  9±0.50                   0.336                  19±0.58   0.336    23±0.80   0.336
  **5h**         13±0.43              0.651                  19±1.00                  \>1.30                 18±0.20   0.163    13±0.50   0.651
  **5i**         13±0.58              0.678                  14±0.58                  0.678                  11±0.20   \>1.36   16±0.12   0.678
  **5j**         15±0.50              0.339                  19±0.50                  0.678                  19±0.58   0.170    17±0.80   0.678
  **5k**         14±1.10              0.678                  22±0.80                  0.339                  19±1.00   0.339    15±0.90   0.678
  **5l**         15±0.90              0.148                  20±0.40                  0.297                  17±0.58   0.148    23±0.40   0.297
  **5m**         15±0.58              0.148                  21±1.00                  0.297                  12±0.10   0.148    23±1.10   0.297
  **5n**         13±1.00              1.18                   22±0.40                  0.592                  20±0.40   1.18     14±0.40   0.592
  **5o**         12±0.43              0.565                  21±0.50                  0.565                  19±0.58   0.141    15±0.60   0.565
  **5p**         14±1.10              0.703                  21±1.00                  0.351                  17±0.80   0.176    14±0.50   0.703
  **5q**         13±0.60              0.693                  21±0.50                  0.347                  20±0.50   0.693    12±0.43   1.39
  **5r**         13±0.58              0.693                  20±0.50                  0.347                  19±0.50   0.693    18±0.20   0.693
  Fluconazole    18±1.10              0.051                  19±1.00                  0.045                  19±0.90   0.047    ND        ND
  Ketoconazole   ND                   ND                     ND                       ND                     ND        ND       29±0.60   0.02

**Note:**

The arithmetic mean of the inhibition zone diameters in mean ± SD.

**Abbreviations:** DIZ, diameter of the inhibition zone; MIC, minimum inhibitory concentration; ND, not determined.
